How much is Architect Therapeutics worth in 2026?

Architect Therapeutics has a current valuation of N/A based on their PE Growth/Expansion round and secondary market data.

How much funding has Architect Therapeutics raised?

Architect Therapeutics has raised N/A in total funding across 1 funding rounds.

Architect Therapeutics

Drug Discovery

Architect Therapeutics valuation and funding history | Last updated: January 1, 2023 | 1 funding rounds

Current Valuation

N/A

As of January 1, 2023

Total Funding Raised

N/A

Across 1 round

Last Round

PE Growth/Expansion

Amount undisclosed

Last Funding

Jan 2023

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
January 1, 2023	PE Growth/Expansion	Undisclosed	N/A	-

Valuation Analysis

Current Valuation Metrics

Architect Therapeutics is currently valued at N/A as of January 1, 2023.

Track Architect Therapeutics Valuation Updates

Get notified when Architect Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Architect Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Architect Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Architect Therapeutics Worth in 2026?

Architect Therapeutics is a leading private company in the Drug Discovery sector. Track Architect Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Architect Therapeutics Valuation is Determined

Private company valuations like Architect Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.